Sameek Roychowdhury, MD, PHD
Academic Title: Professor in the College of Medicine
Research Program: Translational Therapeutics
About Me
More info forI am a medical oncologist who specializes in treating patients with advanced prostate and colorectal cancers, including soft tissue sarcoma. Additionally, I serve as an assistant professor in the Department of Internal Medicine and the Department of Pharmacology at The Ohio State University. Proud to be a Buckeye, I earned my undergraduate degree in molecular genetics at Ohio State and received my medical degree and doctorate in immunology here as well. Since 2012, I have been developing clinical trials focused on genomic alterations. As a member of the Translational Therapeutics Program at the OSUCCC – James, my research team uses genomics to identify optimal therapies for patients, also known as precision oncology. Toward that goal, the team evaluates patients with advanced late-stage cancer, develops diagnostics, tools and methods to analyze and interpret genomics data, and devises therapies to be tested in clinical trials. My precision oncology lab is funded by two National Cancer Institute grants and has partnered with the pharmaceutical industry for implementing new therapies in clinical trials. Two major areas of research for my lab are the use of smart drugs to target cancers driven by FGFR gene mutations and using a cellular mechanism called hypermutation with immunotherapies to boost the immune system. My team has also launched a Body Donation Study for Cancer Research that enables patients and families to help scientists study aggressive cancers. I have published research in well-respected journals on the topic of precision oncology, including Science Translational Medicine, Journal of Clinical Oncology, Journal of the American Medical Association and Journal of Molecular Diagnostics. I’m very proud of the work we do here at OSUCCC – James. It’s an extremely collaborative environment that allows us to develop innovative clinical trials based on the research we do, with the ultimate goal of helping patients enjoy a longer life.
Clinical Expertise
More info for- Stomach Cancers
- Small Intestine Cancer
- Testicular Cancers
- Liver Cancers
- Pancreatic Cancers
- Gallbladder Cancers
- Prostate Cancers
- Gastrointestinal Cancers
- Rectal Cancers
- Anal Gland Cancer
- Esophageal Cancers
Research Interests
More info for- Lymphoproliferative Disorders
- Prostatic Neoplasms
- Neoplasms
- Solitary Fibrous Tumors
- Graft vs Host Disease
- Breast Neoplasms
- Burkitt Lymphoma
- Lymphoma
- Hemangiopericytoma
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Where I See Patients
More info forEducation & Training
More info forGraduate - Allergy \T\ Immunology
- Ohio State University College of Medicine
370 W 9Th Ave, Columbus, OH
Medical School
- Ohio State University College of Medicine
370 W 9Th Ave, Columbus, OH
Fellowship - Medical Oncology
- University of Michigan Medical Center
1500 E Medical Center Dr, Ann Arbor, MI
Fellowship - Pathology - Clinical
- University of Michigan Medical Center
1500 E Medical Center Dr, Ann Arbor, MI
Residency - Internal Medicine
- University of Michigan Medical Center
1500 E Medical Center Dr, Ann Arbor, MI
- Ohio State University College of Medicine
Academic Office & Contact Information
More info forAcademic Office:
Biomedical Research Tower 0996
460 W 12th Ave
Columbus, Ohio 43210-2210Phone:
614-685-5842Email:
roychowdhury.1@osu.eduReviews
More info forPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
Videos
More info forPublications
More info forSeptember 17, 2024FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer.
Stein L, Murugesan K, Reeser JW, Risch Z, Wing MR, Paruchuri A, Samorodnitsky E, Hoskins EL, Dao T, Smith A, Le D, Babcook MA, Chang YS, Avenarius MR, Imam M, Freud AG, Roychowdhury S
NPJ Precis Oncol
August 20, 2024Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes.
Manne A, Esnakula A, Sheel A, Sara A, Manne U, Paluri RK, He K, Yang W, Sohal D, Kasi A, Noonan AM, Mittra A, Hays J, Roychowdhury S, Malalur P, Rahman S, Jin N, Cloyd JM, Tsai S, Ejaz A, Pitter K, Miller E, Thanikachalam K, Dillhoff M, Yu L
Int J Mol Sci
May 30, 2024Myeloid neoplasm with histiocytosis and spleen tyrosine kinase fusion responds to fostamatinib.
Risch Z, Kaffenberger BH, Chung CG, Samorodnitsky E, Hoskins EL, Dao T, Smith A, Wall SA, Brammer J, Reeser JW, Wing MR, Hopkins JF, Albacker LA, Abruzzo LV, Eisele CD, Freud AG, Roychowdhury S, Walsh KE
Haematologica
April 12, 2023The future of fibroblast growth factor receptor inhibitors and mechanisms of resistance for cholangiocarcinoma.
Ruff SM, Roychowdhury S, Pawlik TM
Expert Opin Pharmacother
January 1, 2023Pan-cancer Landscape of Programmed Death Ligand-1 and Programmed Death Ligand-2 Structural Variations.
Hoskins EL, Samorodnitsky E, Wing MR, Reeser JW, Hopkins JF, Murugesan K, Kuang Z, Vella R, Stein L, Risch Z, Yu L, Adebola S, Paruchuri A, Carpten J, Chahoud J, Edge S, Kolesar J, McCarter M, Nepple KG, Reilley M, Scaife C, Tripathi A, Single N, Huang RSP, Albacker LA, Roychowdhury S
JCO Precis Oncol
May 22, 2022Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer.
Murugesan K, Jin DX, Comment LA, Fabrizio D, Hegde PS, Elvin JA, Alexander B, Levy MA, Frampton GM, Montesion M, Roychowdhury S, Kurzrock R, Ross JS, Albacker LA, Huang RSP
Oncologist
February 14, 2022Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma With Comprehensive Genomic Profiling.
Silverman IM, Li M, Murugesan K, Krook MA, Javle MM, Kelley RK, Borad MJ, Roychowdhury S, Meng W, Yilmazel B, Milbury C, Shewale S, Feliz L, Burn TC, Albacker LA
J Mol Diagn
August 3, 2021Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
Javle M, Roychowdhury S, Kelley RK, Sadeghi S, Macarulla T, Weiss KH, Waldschmidt DT, Goyal L, Borbath I, El-Khoueiry A, Borad MJ, Yong WP, Philip PA, Bitzer M, Tanasanvimon S, Li A, Pande A, Soifer HS, Shepherd SP, Moran S, Zhu AX, Bekaii-Saab TS, Abou-Alfa GK
Adv Psychosom Med
December 3, 2020Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance.
Krook MA, Reeser JW, Ernst G, Barker H, Wilberding M, Li G, Chen HZ, Roychowdhury S
Br J Cancer
November 23, 2020Characterization of clonal evolution in microsatellite unstable metastatic cancers through multi-regional tumor sequencing.
Bonneville R, Paruchuri A, Wing MR, Krook MA, Reeser JW, Chen HZ, Dao T, Samorodnitsky E, Smith AM, Yu L, Nowacki N, Chen W, Roychowdhury S
Mol Cancer Res
June 25, 2020Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial.
Makawita S, K Abou-Alfa G, Roychowdhury S, Sadeghi S, Borbath I, Goyal L, Cohn A, Lamarca A, Oh DY, Macarulla T, T Shroff R, Howland M, Li A, Cho T, Pande A, Javle M
Future Oncol
April 6, 2020Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer.
Wu C, Williams TM, Robb R, Webb A, Wei L, Chen W, Mikhail S, Ciombor KK, Cardin DB, Timmers C, Krishna SG, Arnold M, Harzman A, Abdel-Misih S, Roychowdhury S, Bekaii-Saab T, Wuthrick E
Clin Cancer Res
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Roychowdhury has reported no relationships with companies or entities.
Patient Comments
Drs. Roychowdhury and Reeser were colleagal while providing new information to enable my treatment decisions.
Very smooth
Every aspect of our encounter was fantastic. Professional and kind. I felt cared about and assured
Great doctor and nurses.
Care provider always treats me as if I am their only patient. Above and beyond in providing care and information.
Felt they weren't prepared for my visit. We were told of new treatment options but none were discussed due to not having info ready.
Seem understaffed, rushed, behind, seen some errors, delays with team reviewing my chart test results for days. Not confident yet.
The oncologist was the ONLY health care professional in 18 months was recognized that cancer is a human experience as well as a psychological event.
This was the first time I left after meeting a provider for the first time that I felt encouraged & didn't leave in time.
1. Excellent. 3. Great.